Selection of the candidate compound at an early stage of new drug development: retrospective pharmacokinetic and metabolic evaluations of valsartan using common marmosets

References

• Anand IS, Deswal A, Kereiakes DJ, Purkayastha D, Zappe DH. 2010. Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vasc Health Risk Manag. 6:449–455.
   PubMedGoogle Scholar
• Bottorff MB, Tenero DM. 1999. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy. 19(4 Pt 2):73S–78S.
   PubMed Web of Science ®Google Scholar
• Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Mueller P, Gasparo M. 1995. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev. 13(3):230–250.
   Google Scholar
• Di L, Feng B, Goosen TC, Lai Y, Steyn SJ, Varma MV, Obach RS. 2013. A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. Drug Metab Dispos. 41(12):1975–1993.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2009. ICH topic M3 (R2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. London (UK): European Medicines Agency.
   Google Scholar
• Flesch G, Müller P, Lloyd P. 1997. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 52(2):115–120.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. 1996. Drug Approval Package: Diovan (Valsartan) NDA#020665, Review and evaluation of pharmacology and toxicology data. https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/020665_s000.pdf. (CDER’s historical data file)
   Google Scholar
• Food and Drug Administration. 2016. Guidance for industry: safety testing of drug metabolites. Silver Spring (MD): US Department Health and Human Services FaDA, Center for Drug Evaluation and Research.
   Google Scholar
• Göktaş MT, Pepedil F, Karaca Ö, Kalkışım S, Cevik L, Gumus E, Guven GS, Babaoglu MO, Bozkurt A, Yasar U. 2016. Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients. Eur Rev Med Pharmacol Sci. 20(11):2460–2467.
   PubMed Web of Science ®Google Scholar
• Hamid KA, Lin Y, Gao Y, Katsumi H, Sakane T, Yamamoto A. 2009. The effect of Wellsolve, a novel solubilizing agent, on the intestinal barrier function and intestinal absorption of griseofulvin in rats. Biol Pharm Bull. 32(11):1898–1905.
   PubMed Web of Science ®Google Scholar
• Hedner T, Himmelmann A. 1999. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J Hypertens. 17(1):129–136.
   PubMed Web of Science ®Google Scholar
• Hirvensalo P, Tornio A, Launiainen T, Paile‐Hyvärinen M, Tapaninen T, Neuvonen M, Backman JT, Niemi M. 2020. UGT1A3 and sex are major determinants of telmisartan pharmacokinetics-a comprehensive pharmacogenomic study. Clin Pharmacol Ther. 108(4):885–895.
   PubMed Web of Science ®Google Scholar
• Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F. 1996. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens. 14(9):1147–1151.
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, et al. 2009. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol. 49(5):513–533.
   PubMed Web of Science ®Google Scholar
• Hughes JP, Rees S, Kalindjian SB, Philpott KL. 2011. Principles of early drug discovery. Br J Pharmacol. 162(6):1239–1249.
   PubMed Web of Science ®Google Scholar
• Huskey SE, Miller RR, Chiu SH. 1993. N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans. Drug Metab Dispos. 21(5):792–799.
   PubMed Web of Science ®Google Scholar
• Iriarte G, Ferreirós N, Ibarrondo I, Alonso RM, Maguregui MI, Jiménez RM. 2007. Biovalidation of an SPE-HPLC-UV-fluorescence method for the determination of valsartan and its metabolite valeryl-4-hydroxy-valsartan in human plasma. J Sep Sci. 30(14):2231–2240.
   PubMed Web of Science ®Google Scholar
• Jones RD, Jones HM, Rowland M, Gibson CR, Yates JWT, Chien JY, Ring BJ, Adkison KK, Ku MS, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci. 100(10):4074–4089.
   PubMed Web of Science ®Google Scholar
• Kirsten R, Nelson K, Kirsten D, Heintz B. 1998. Clinical pharmacokinetics of vasodilators. Part I. Clin Pharmacokinet. 34(6):457–482.
   PubMed Web of Science ®Google Scholar
• Korte S, Everitt J. 2019. The common marmoset in captivity and biomedical research. American College of Laboratory Animal Medicine. Cambridge (MA): Academic Press. Chapter 27. In: The use of the marmoset in toxicity testing and nonclinical safety assessment studies; p. 493–513.
   Google Scholar
• Kusama T, Toda A, Shimizu M, Uehara S, Inoue T, Uno Y, Utoh M, Sasaki E, Yamazaki H. 2018. Association with polymorphic marmoset cytochrome P450 2C19 of in vivo hepatic clearances of chirally separated R-omeprazole and S-warfarin using individual marmoset physiologically based pharmacokinetic models. Xenobiotica. 48(10):1072–1077.
   PubMed Web of Science ®Google Scholar
• Layne DG, Power RA. 2003. Husbandry, handling, and nutrition for marmosets. Comp Med. 53(4):351–359.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang G, Wang L-S, Zhang W, Tan Z-R, Fan L, Chen B-L, Li Q, Liu J, Tu J-H, et al. 2009. Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica. 39(10):788–793.
   PubMed Web of Science ®Google Scholar
• Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. 1995. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 58(6):641–649.
   PubMed Web of Science ®Google Scholar
• Mahmood I. 2010. Theoretical versus empirical allometry: facts behind theories and application to pharmacokinetics. J Pharm Sci. 99(7):2927–2933.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Uehara S, Kamimura H, Ikeda H, Maeda S, Hattori M, Nishiwaki M, Kato K, Yamazaki H. 2021. Human total clearance values and volumes of distribution of typical human cytochrome P450 2C9/19 substrates predicted by single-species allometric scaling using pharmacokinetic data sets in common marmosets genotyped for P450 2C19. Xenobiotica. 51(4):479–493.
   PubMed Web of Science ®Google Scholar
• McClellan KJ, Markham A. 1998. Telmisartan. Drugs. 56(6):1039–1044.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Hirabayashi H. 2017. Comparison of predictability for human pharmacokinetics parameters among monkeys, rats, and chimeric mice with humanised liver. Xenobiotica. 47(12):1052–1063.
   PubMed Web of Science ®Google Scholar
• Miyamoto M, Iwasaki S, Chisaki I, Nakagawa S, Amano N, Kosugi Y, Hirabayashi H. 2019. Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver. Xenobiotica. 49(12):1379–1387.
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Murota N, Sato S, Nii K, Kouhei Y, Taniguchi M, Inoue R, Nishime C, Tsutsumi H. 2018. Approaches of validation of a 2-week combined repeated oral dose toxicity study with plasma micro sampling toxicokinetics (PMS-TK) in common marmosets. J Toxicol Sci. 43(11):685–695.
   PubMedGoogle Scholar
• Nagilla R, Nord M, McAtee JJ, Jolivette LJ. 2011. Cassette dosing for pharmacokinetic screening in drug discovery: comparison of clearance, volume of distribution, half-life, mean residence time, and oral bioavailability obtained by cassette and discrete dosing in rats. J Pharm Sci. 100(9):3862–3874.
   PubMed Web of Science ®Google Scholar
• Nakada N. 2017. Evaluation of the utility of chimeric mice with humanized livers for the characterization and profiling of the metabolites of a selective inhibitor (YM543) of the sodium-glucose cotransporter 2. Pharm Res. 34(4):874–886.
   PubMed Web of Science ®Google Scholar
• Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K. 2005. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes. Xenobiotica. 35(6):589–602.
   PubMed Web of Science ®Google Scholar
• Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. 1993. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 35(3):290–297.
   PubMed Web of Science ®Google Scholar
• Orsi A, Rees D, Andreini I, Venturella S, Cinelli S, Oberto G. 2011. Overview of the marmoset as a model in nonclinical development of pharmaceutical products. Regul Toxicol Pharmacol. 59(1):19–27.
   PubMed Web of Science ®Google Scholar
• Poirier A, Cascais AC, Funk C, Lavé T. 2009. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data. Chem Biodivers. 6(11):1975–1987.
   PubMed Web of Science ®Google Scholar
• Prior H, Haworth R, Labram B, Roberts R, Wolfreys A, Sewell F. 2020. Justification for species selection for pharmaceutical toxicity studies. Toxicol Res (Camb)). 9(6):758–770.
   PubMed Web of Science ®Google Scholar
• Riede J, Poller B, Umehara K, Huwyler J, Camenisch G. 2016. New IVIVE method for the prediction of total human clearance and relative elimination pathway contributions from in vitro hepatocyte and microsome data. Eur J Pharm Sci. 86:96–102.
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, Jones HM, Rowland M, Jones RD, Yates JWT, Ku MS, Gibson CR, He H, et al. 2011. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci. 100(10):4090–4110.
   PubMed Web of Science ®Google Scholar
• Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, et al. 2018. A decade in the MIST: Learnings from investigations of drug metabolites in drug development under the “Metabolites in Safety Testing” regulatory guidance. Drug Metab Dispos. 46(6):865–878.
   PubMed Web of Science ®Google Scholar
• Smith D, Trennery P, Farningham D, Klapwijk J. 2001. The selection of marmoset monkeys (Callithrix jacchus) in pharmaceutical toxicology. Lab Anim. 35(2):117–130.
   PubMedGoogle Scholar
• Smith DA, Beaumont K, Maurer TS, Li D. 2018. Relevance of half-life in drug design. J Med Chem. 61(10):4273–4282.
   PubMed Web of Science ®Google Scholar
• Soars MG, Riley RJ, Burchell B. 2001. Evaluation of the marmoset as a model species for drug glucuronidation. Xenobiotica. 31(12):849–860.
   PubMed Web of Science ®Google Scholar
• Son YW, Choi HN, Che JH, Kang BC, Yun JW. 2020. Advances in selecting appropriate non-rodent species for regulatory toxicology research: policy, ethical, and experimental considerations. Regul Toxicol Pharmacol. 116:104757.
   PubMed Web of Science ®Google Scholar
• Stangier J, Schmid J, Türck D, Switek H, Verhagen A, Peeters PA, van Marle SP, Tamminga WJ, Sollie FA, Jonkman JH. 2000a. Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers. J Clin Pharmacol. 40(12 Pt):1):1312–1322.
   Web of Science ®Google Scholar
• Stangier J, Su CA, Roth W. 2000b. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 28(4):149–167.
   PubMed Web of Science ®Google Scholar
• Sun P, Wang C, Liu Q, Meng Q, Zhang A, Huo X, Sun H, Liu K. 2014. OATP and MRP2-mediated hepatic uptake and biliary excretion of eprosartan in rat and human. Pharmacol Rep. 66(2):311–319.
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Kiukaanniemi K, Pelkonen O. 2000. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol. 56(2):135–140.
   PubMed Web of Science ®Google Scholar
• Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, Zariffa N, Boyle D, Jorkasky D. 1998. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos. 19(6):351–356.
   PubMed Web of Science ®Google Scholar
• Tess DA, Eng H, Kalgutkar AS, Litchfield J, Edmonds DJ, Griffith DA, Varma MVS. 2020. Predicting the human hepatic clearance of acidic and zwitterionic drugs. J Med Chem. 63(20):11831–11844.
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, Kawano M, Shimizu M, Toda A, Utoh M, Sasaki E, Yamazaki H. 2016. Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug Metab Dispos. 44(7):911–915.
   PubMed Web of Science ®Google Scholar
• Uno Y, Uehara S, Inoue T, Kawamura S, Murayama N, Nishikawa M, Ikushiro S, Sasaki E, Yamazaki H. 2020. Molecular characterization of functional UDP-glucuronosyltransferases 1A and 2B in common marmosets. Biochem Pharmacol. 172:113748.
   PubMed Web of Science ®Google Scholar
• Wajima T, Yano Y, Fukumura K, Oguma T. 2004. Prediction of human pharmacokinetic profile in animal scale up based on normalizing time course profiles. J Pharm Sci. 93(7):1890–1900.
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Flesch G, Müller P, Winkler T, Kriemler HP, Bühlmayer P, De Gasparo M. 1997. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 27(1):59–71.
   PubMed Web of Science ®Google Scholar
• White RE, Manitpisitkul P. 2001. Pharmacokinetic theory of cassette dosing in drug discovery screening. Drug Metab Dispos. 29(7):957–966.
   PubMed Web of Science ®Google Scholar
• Williamson KM, Patterson JH, McQueen RH, Adams KF Jr, Pieper JA. 1998. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 63(3):316–323.
   PubMed Web of Science ®Google Scholar
• Yamada A, Maeda K, Ishiguro N, Tsuda Y, Igarashi T, Ebner T, Roth W, Ikushiro S, Sugiyama Y. 2011. The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers. Pharmacogenet Genomics. 21(9):523–530.
   PubMed Web of Science ®Google Scholar
• Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. 2006. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos. 34(7):1247–1254.
   PubMed Web of Science ®Google Scholar
• Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E. 2001. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit. 23(4):369–373.
   PubMed Web of Science ®Google Scholar
• Zühlke U, Weinbauer G. 2003. The common marmoset (Callithrix jacchus) as a model in toxicology. Toxicol Pathol. 31(Suppl):123–127.
   PubMedGoogle Scholar